A peptide nucleic acid-based pretargeting approach using 161Tb for radionuclide therapy in a murine tumor model
Authors:
- Xin XiangXXXin Xiang
- Hua PangHPHua Pang
- Zhengjie WangZWZhengjie Wang
Open Access
- 30 January 2026
- journal article
- research article
- Published by Springer Nature in EJNMMI Research
- Vol. 16 (1)
Abstract
Although molecular tumor-targeting peptides modified with albumin-binding domains can enhance tumor probe uptake and prolong tumor retention time, the prolKeywords
Funding Information
- National Natural Science Foundation (82102093)
- Innovative Research Group Project of the National Natural Science Foundation of China (82472019)
- Chongqing Municipal Science and Technology Bureau (CSTB2024TIAD-STX0048)
- Natural Science Foundation of Chongqing Municipality (CSTB2025NSCQ-GPX1138)
- Natural Science Foundation of Chongqing Municipality (CSTB2023NSCQ-MSX0097)
This publication has 42 references indexed in Scilit:
- Development of [177Lu]Lu-LNC1010 for peptide receptor radionuclide therapy of nasopharyngeal carcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical settingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2024
- Synthesis, preclinical, and initial clinical evaluation of integrin αVβ3 and gastrin-releasing peptide receptor (GRPR) dual-targeting radiotracer [68Ga]Ga-RGD-RM26-03European Journal of Nuclear Medicine and Molecular Imaging, 2024
- RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactionsCancer Medicine, 2024
- A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine TumorsJAMA Network Open, 2021
- Dose escalation of an Evans blue–modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumorsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Nanoparticles as new tools for inhibition of cancer angiogenesisJournal of Cellular Physiology, 2017
- Radiolabelled RGD peptides for imaging and therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Pretargeting using peptide nucleic acidCancer, 1997